Revive Therapeutics Ltd.

Revive Therapeutics to Acquire DiagnaMed's Molecular Hydrogen Program for ALS and Brain Disorders

3 months ago

• Revive Therapeutics has signed a letter of intent to acquire DiagnaMed's molecular hydrogen intellectual property portfolio, including an FDA Orphan Drug Designation for ALS treatment. • The acquisition includes patent applications for novel pharmaceutical-grade hydrogen-producing compositions targeting various neurological conditions including Dementia, Parkinson's disease, and mental health disorders. • The deal aims to accelerate development of molecular hydrogen therapy for ALS, which affects 50,000 patients in the US and Europe, with potential closing expected by March 31, 2025.

Revive Therapeutics Focuses R&D on Bucillamine for Infectious Diseases and Nerve Agent Exposure

4 months ago

• Revive Therapeutics is prioritizing the development of Bucillamine for medical countermeasures against nerve agent exposure, leveraging its antioxidant properties. • A research partnership with Defence R&D Canada is evaluating Bucillamine's potential to mitigate nerve agent-induced brain injury by enhancing GABA receptor function. • Revive is also exploring Bucillamine as a treatment for Long COVID, with plans to submit a Phase 2 study protocol to the FDA by the end of Q1 2025. • The FDA has provided feedback on study design for Long COVID, recommending a new IND application referencing data from a previous Phase 3 COVID-19 trial.